STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 99 filers reported holding STOKE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.42 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,975 | -62.9% | 2,278 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $24,215 | +94.2% | 2,278 | +52.2% | 0.00% | – |
| Q1 2023 | $12,470 | -10.3% | 1,497 | 0.0% | 0.00% | -100.0% |
| Q4 2022 | $13,907 | -26.8% | 1,497 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $19,000 | 0.0% | 1,497 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $19,000 | -40.6% | 1,497 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $32,000 | -11.1% | 1,497 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $36,000 | -5.3% | 1,497 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $38,000 | -24.0% | 1,497 | 0.0% | 0.00% | -50.0% |
| Q2 2021 | $50,000 | +19.0% | 1,497 | +38.7% | 0.00% | 0.0% |
| Q1 2021 | $42,000 | -37.3% | 1,079 | 0.0% | 0.00% | -33.3% |
| Q4 2020 | $67,000 | +86.1% | 1,079 | 0.0% | 0.00% | +50.0% |
| Q3 2020 | $36,000 | +38.5% | 1,079 | 0.0% | 0.00% | +100.0% |
| Q2 2020 | $26,000 | -23.5% | 1,079 | -27.1% | 0.00% | -50.0% |
| Q1 2020 | $34,000 | +54.5% | 1,480 | +94.5% | 0.00% | +100.0% |
| Q4 2019 | $22,000 | +37.5% | 761 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $16,000 | – | 761 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 296,822 | $7,551,000 | 1.86% |
| RTW INVESTMENTS, LP | 3,644,248 | $92,710,000 | 1.40% |
| Cormorant Asset Management, LP | 1,278,276 | $32,519,000 | 1.32% |
| Redmile Group, LLC | 2,381,958 | $60,597,000 | 1.06% |
| HighVista Strategies LLC | 47,594 | $1,211,000 | 0.80% |
| Birchview Capital, LP | 15,000 | $382,000 | 0.26% |
| GILDER GAGNON HOWE & CO LLC | 1,123,355 | $28,578,000 | 0.15% |
| Artal Group S.A. | 250,000 | $6,360,000 | 0.14% |
| Tekla Capital Management LLC | 99,263 | $2,525,000 | 0.08% |
| Casdin Capital, LLC | 120,000 | $3,053,000 | 0.08% |